These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 19331590)

  • 1. Ethnic differences in drug metabolism and toxicity from chemotherapy.
    Phan VH; Moore MM; McLachlan AJ; Piquette-Miller M; Xu H; Clarke SJ
    Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):243-57. PubMed ID: 19331590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
    Deeken JF; Figg WD; Bates SE; Sparreboom A
    Anticancer Drugs; 2007 Feb; 18(2):111-26. PubMed ID: 17159598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
    van Schaik RH
    Invest New Drugs; 2005 Dec; 23(6):513-22. PubMed ID: 16267627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
    Bosch TM; Meijerman I; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
    Chen S; Sutiman N; Zhang CZ; Yu Y; Lam S; Khor CC; Chowbay B
    Drug Metab Rev; 2016 Nov; 48(4):502-540. PubMed ID: 27546072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.
    Bertholee D; Maring JG; van Kuilenburg AB
    Clin Pharmacokinet; 2017 Apr; 56(4):317-337. PubMed ID: 27641154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.
    Klotz U
    Clin Pharmacokinet; 2007; 46(4):271-9. PubMed ID: 17375979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.
    Phan VH; Tan C; Rittau A; Xu H; McLachlan AJ; Clarke SJ
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1395-410. PubMed ID: 21950349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.
    Kerb R; Fux R; Mörike K; Kremsner PG; Gil JP; Gleiter CH; Schwab M
    Lancet Infect Dis; 2009 Dec; 9(12):760-74. PubMed ID: 19926036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic factors affecting drug disposition in Asian cancer patients.
    Syn NL; Yong WP; Lee SC; Goh BC
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1879-92. PubMed ID: 26548636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer pharmacogenomics: achievements in basic research.
    Nakajima M; Yokoi T
    Int J Clin Oncol; 2005 Feb; 10(1):14-9. PubMed ID: 15729595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.
    Hor SY; Lee SC; Wong CI; Lim YW; Lim RC; Wang LZ; Fan L; Guo JY; Lee HS; Goh BC; Tan T
    Pharmacogenomics J; 2008 Apr; 8(2):139-46. PubMed ID: 17876342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
    Bosch TM
    Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethnic differences in drug metabolism.
    Zhou HH; Liu ZQ
    Clin Chem Lab Med; 2000 Sep; 38(9):899-903. PubMed ID: 11097347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28].
    Sai K; Sawada J; Minami H
    Yakugaku Zasshi; 2008 Apr; 128(4):575-84. PubMed ID: 18379174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.
    Rochat B
    Clin Pharmacokinet; 2005; 44(4):349-66. PubMed ID: 15828850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
    Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
    Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients.
    Sparreboom A; Marsh S; Mathijssen RH; Verweij J; McLeod HL
    Invest New Drugs; 2004 Aug; 22(3):285-9. PubMed ID: 15122075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacogenetics of the response to warfarin in Chinese.
    Lam MP; Cheung BM
    Br J Clin Pharmacol; 2012 Mar; 73(3):340-7. PubMed ID: 22023024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline pharmacogenetics of paclitaxel for cancer treatment.
    Hertz DL
    Pharmacogenomics; 2013 Jul; 14(9):1065-84. PubMed ID: 23837481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.